Another cell therapy biotech has run out of steam, this time before ever reaching the clinic. | Another cell therapy biotech ...

Gumokimab, also called AK111, is an anti-IL-17A monoclonal antibody that Akeso has already tested out in a separate phase 3 ...

Amid a frozen over IPO landscape, LB Pharmaceuticals has filed to go public to fund a pivotal schizophrenia study for its ...

The candidates are sourced from Arnatar’s next-gen RNA discovery engine, dubbed DARGER for dual-functional antisense RNA for ...

With the FDA’s go-ahead, Coya plans to launch a multicenter phase 2 trial of COYA 302 in patients with ALS, CEO Arun ...

At AbbVie, bretisilocin will slot into a well-established neuroscience unit. AbbVie has deals with Gedeon Richter, the source ...

PDS Biotech has reported final phase 2 data on PDS0101 in the tough-to-treat head and neck cancer setting, linking a combination of the immunotherapy and Keytruda to median overall survival (OS) of 39 ...

By: Raymund Santos, Senior Manager, Quality Control Bioanalytics, AGC BiologicsAelén Mabillé, Manager, Quality Control Raw ...

The Supreme Court is allowing the Trump administration to axe $783 million in federal research funding, reversing a lower ...

Jazz Pharmaceuticals has struck a deal to bolster its epilepsy ambitions, paying Saniona $42.5 million upfront for a ...

Lighthouse Pharmaceuticals’ plan to become a beacon of hope for Alzheimer’s disease patients has received almost $50 million ...

The first half of 2025 was brutal for biotech, but investors are still keen on therapeutics in several indications and silver ...